Aerosol delivery of stabilized polyester-siRNA nanoparticles to silence gene expression in orthotopic lung tumors

Yunfeng Yan, Kejin Zhou, Hu Xiong, Jason B. Miller, Edward A. Motea, David A. Boothman, Li Liu, Daniel J. Siegwart

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Tremendous progress has been made in the development of delivery carriers for small RNA therapeutics. However, most achievements have focused on the treatment of liver-associated diseases because conventional lipid and lipidoid nanoparticles (LNPs) readily accumulate in the liver after intravenous (i.v.) administration. Delivering RNAs to other organs and tumor tissues remains an ongoing challenge. Here, we utilized a 540-member combinatorial functional polyester library to discover nanoparticles (NPs) that enable efficacious siRNA delivery to A549 lung cancer cells in vitro and in vivo. PE4K-A13–0.33C6 and PE4K-A13–0.33C10 NPs were efficiently internalized into A549-Luc cells within 4 h. The addition of PEG 2000 DMG lipid or Pluronic F-127 onto the surface of the polyplexes reduced the surface charge of NPs, resulting in an increase of serum stability. We then explored aerosol delivery of stabilized PE4K-A13–0.33C6 and PE4K-A13–0.33C10 NPs to implanted orthotopic lung tumors. We found that by altering the administration route from i.v. to aerosol, the NPs could avoid liver accumulation and instead be specifically localized only in the lungs. This resulted in significant gene silencing in the A549 orthotopic lung tumors. Due to the ability to deliver siRNA to non-liver targets, this approach provides a privileged route for gene silencing in the lungs.

Original languageEnglish (US)
Pages (from-to)84-93
Number of pages10
JournalBiomaterials
Volume118
DOIs
StatePublished - Feb 1 2017

Fingerprint

Polyesters
Aerosols
Gene expression
Nanoparticles
Small Interfering RNA
Tumors
Gene Expression
Lung
Liver
Neoplasms
Gene Silencing
RNA
Intravenous Administration
Lipids
Genes
Poloxamer
Aptitude
Surface charge
Polyethylene glycols
Liver Diseases

Keywords

  • Cancer
  • Drug delivery
  • Functional polyesters
  • Nanoparticles
  • siRNA

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Aerosol delivery of stabilized polyester-siRNA nanoparticles to silence gene expression in orthotopic lung tumors. / Yan, Yunfeng; Zhou, Kejin; Xiong, Hu; Miller, Jason B.; Motea, Edward A.; Boothman, David A.; Liu, Li; Siegwart, Daniel J.

In: Biomaterials, Vol. 118, 01.02.2017, p. 84-93.

Research output: Contribution to journalArticle

Yan, Yunfeng ; Zhou, Kejin ; Xiong, Hu ; Miller, Jason B. ; Motea, Edward A. ; Boothman, David A. ; Liu, Li ; Siegwart, Daniel J. / Aerosol delivery of stabilized polyester-siRNA nanoparticles to silence gene expression in orthotopic lung tumors. In: Biomaterials. 2017 ; Vol. 118. pp. 84-93.
@article{a0a1e1c571c14e2995937369f530a229,
title = "Aerosol delivery of stabilized polyester-siRNA nanoparticles to silence gene expression in orthotopic lung tumors",
abstract = "Tremendous progress has been made in the development of delivery carriers for small RNA therapeutics. However, most achievements have focused on the treatment of liver-associated diseases because conventional lipid and lipidoid nanoparticles (LNPs) readily accumulate in the liver after intravenous (i.v.) administration. Delivering RNAs to other organs and tumor tissues remains an ongoing challenge. Here, we utilized a 540-member combinatorial functional polyester library to discover nanoparticles (NPs) that enable efficacious siRNA delivery to A549 lung cancer cells in vitro and in vivo. PE4K-A13–0.33C6 and PE4K-A13–0.33C10 NPs were efficiently internalized into A549-Luc cells within 4 h. The addition of PEG 2000 DMG lipid or Pluronic F-127 onto the surface of the polyplexes reduced the surface charge of NPs, resulting in an increase of serum stability. We then explored aerosol delivery of stabilized PE4K-A13–0.33C6 and PE4K-A13–0.33C10 NPs to implanted orthotopic lung tumors. We found that by altering the administration route from i.v. to aerosol, the NPs could avoid liver accumulation and instead be specifically localized only in the lungs. This resulted in significant gene silencing in the A549 orthotopic lung tumors. Due to the ability to deliver siRNA to non-liver targets, this approach provides a privileged route for gene silencing in the lungs.",
keywords = "Cancer, Drug delivery, Functional polyesters, Nanoparticles, siRNA",
author = "Yunfeng Yan and Kejin Zhou and Hu Xiong and Miller, {Jason B.} and Motea, {Edward A.} and Boothman, {David A.} and Li Liu and Siegwart, {Daniel J.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.biomaterials.2016.12.001",
language = "English (US)",
volume = "118",
pages = "84--93",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Aerosol delivery of stabilized polyester-siRNA nanoparticles to silence gene expression in orthotopic lung tumors

AU - Yan, Yunfeng

AU - Zhou, Kejin

AU - Xiong, Hu

AU - Miller, Jason B.

AU - Motea, Edward A.

AU - Boothman, David A.

AU - Liu, Li

AU - Siegwart, Daniel J.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Tremendous progress has been made in the development of delivery carriers for small RNA therapeutics. However, most achievements have focused on the treatment of liver-associated diseases because conventional lipid and lipidoid nanoparticles (LNPs) readily accumulate in the liver after intravenous (i.v.) administration. Delivering RNAs to other organs and tumor tissues remains an ongoing challenge. Here, we utilized a 540-member combinatorial functional polyester library to discover nanoparticles (NPs) that enable efficacious siRNA delivery to A549 lung cancer cells in vitro and in vivo. PE4K-A13–0.33C6 and PE4K-A13–0.33C10 NPs were efficiently internalized into A549-Luc cells within 4 h. The addition of PEG 2000 DMG lipid or Pluronic F-127 onto the surface of the polyplexes reduced the surface charge of NPs, resulting in an increase of serum stability. We then explored aerosol delivery of stabilized PE4K-A13–0.33C6 and PE4K-A13–0.33C10 NPs to implanted orthotopic lung tumors. We found that by altering the administration route from i.v. to aerosol, the NPs could avoid liver accumulation and instead be specifically localized only in the lungs. This resulted in significant gene silencing in the A549 orthotopic lung tumors. Due to the ability to deliver siRNA to non-liver targets, this approach provides a privileged route for gene silencing in the lungs.

AB - Tremendous progress has been made in the development of delivery carriers for small RNA therapeutics. However, most achievements have focused on the treatment of liver-associated diseases because conventional lipid and lipidoid nanoparticles (LNPs) readily accumulate in the liver after intravenous (i.v.) administration. Delivering RNAs to other organs and tumor tissues remains an ongoing challenge. Here, we utilized a 540-member combinatorial functional polyester library to discover nanoparticles (NPs) that enable efficacious siRNA delivery to A549 lung cancer cells in vitro and in vivo. PE4K-A13–0.33C6 and PE4K-A13–0.33C10 NPs were efficiently internalized into A549-Luc cells within 4 h. The addition of PEG 2000 DMG lipid or Pluronic F-127 onto the surface of the polyplexes reduced the surface charge of NPs, resulting in an increase of serum stability. We then explored aerosol delivery of stabilized PE4K-A13–0.33C6 and PE4K-A13–0.33C10 NPs to implanted orthotopic lung tumors. We found that by altering the administration route from i.v. to aerosol, the NPs could avoid liver accumulation and instead be specifically localized only in the lungs. This resulted in significant gene silencing in the A549 orthotopic lung tumors. Due to the ability to deliver siRNA to non-liver targets, this approach provides a privileged route for gene silencing in the lungs.

KW - Cancer

KW - Drug delivery

KW - Functional polyesters

KW - Nanoparticles

KW - siRNA

UR - http://www.scopus.com/inward/record.url?scp=85003712729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003712729&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2016.12.001

DO - 10.1016/j.biomaterials.2016.12.001

M3 - Article

C2 - 27974266

AN - SCOPUS:85003712729

VL - 118

SP - 84

EP - 93

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -